ImmuPharma plc
IMM.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £5,008 | £6,024 | £5,574 | £16,577 |
| - Cash | £237 | £208 | £668 | £1,649 |
| + Debt | £0 | £0 | £0 | £1 |
| Enterprise Value | £4,771 | £5,815 | £4,906 | £14,928 |
| Revenue | £0 | £0 | £0 | £118 |
| % Growth | – | – | -100% | – |
| Gross Profit | -£64 | -£38 | -£118 | £118 |
| % Margin | – | – | – | 100% |
| EBITDA | -£2,611 | -£3,025 | -£2,911 | -£8,703 |
| % Margin | – | – | – | -7,353.6% |
| Net Income | -£2,483 | -£2,922 | -£3,807 | -£8,174 |
| % Margin | – | – | – | -6,906.6% |
| EPS Diluted | -0.006 | -0.008 | -0.013 | -0.033 |
| % Growth | 25.9% | 35.7% | 61.2% | – |
| Operating Cash Flow | -£1,769 | -£1,364 | -£2,347 | -£4,833 |
| Capital Expenditures | -£2 | £0 | -£106 | -£51 |
| Free Cash Flow | -£1,771 | -£1,364 | -£2,453 | -£4,884 |